The results of a nine-month investigation by health regulators in the European Union should be comforting for anyone taking Ozempic and other similar drugs to treat type 2 diabetes and/or obesity. EU officials said Friday that they failed to find evidence of a causative link between GLP-1 drugs and an increased risk…
The UK has embarked on a first-of-its-kind initiative that will make the lives of many diabetics much easier. The country is set to provide artificial pancreas devices to tens of thousands of people living with type 1 diabetes. The recently approved devices should eliminate the need for patients to constantly measure…
Getty Images
Pharmaceutical company Eli Lilly is making a plea to some of its customers: stop hoarding our weight loss drugs. In a new Oscar-themed commercial set to run on TV this weekend, the drugmaker is not-so-subtly telling people to stay away from its new blockbuster medications if they’re only looking to lose a few pounds.…
Another week, another study finding that Ozempic/Wegovy and similar drugs may do a lot more than just help people lose weight. New research has found that patients who start taking GLP-1 drugs are less likely to be diagnosed with depression and anxiety afterward, compared to similar patients not on the drug. The…
Your snack habit may be even more calorie-dense than you think, recent research suggests. A study estimated that snacking contributes to around 20% of an average American’s daily caloric intake, and these snacks often add little nutritional value. The scientists found, though, that people with type 2 diabetes seem to…
New research shows that tirzepatide, the latest FDA-approved obesity drug, really can help people lose substantial amounts of weight—but only if they continue taking it. The study found that people who stopped taking tirzepatide after 36 weeks regained much of their lost weight within a year, while those who continued…
A study out this week suggests that semaglutide—the active ingredient in popular obesity drug Wegovy—might be able to help people struggling with alcohol use disorder, too. In a small sample of cases, researchers found evidence that people who took semaglutide for weight loss also experienced a significant reduction…
There’s officially a new and fierce competitor for Novo Nordisk’s Wegovy (semaglutide) when it comes to weight loss. On Wednesday, the Food and Drug Administration approved the drug tirzepatide, developed by Eli Lilly, as a treatment for obesity. The weekly injectable drug will be sold under the brand name Zepbound.
Health officials in Austria are the latest to warn the public to stay away from sketchy sources of semaglutide, the active ingredient in popular weight loss drugs Wegovy and Ozempic, following recent reports of severe adverse effects linked to counterfeit products. Residents have reportedly been hospitalized with…
